Zwitterionic compounds and uses thereof
US-2026069726-A1 · Mar 12, 2026 · US
being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
being further substituted by nitrogen atoms, not being part of nitro or nitroso groups · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07C335/20 |
| Official title | being further substituted by nitrogen atoms, not being part of nitro or nitroso groups |
| Display label | being further substituted by nitrogen atoms, not being part of nitro or nitroso groups |
| Total patents | 25 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is stable.
| Year | Patents |
|---|---|
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
1,4-diureas and 1,4-dithioureas and uses thereof
US-2025241890-A1 · Jul 31, 2025 · US
Novel compound comprising ester group and uses thereof
US-2024336632-A1 · Oct 10, 2024 · US
Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith
US-12017975-B2 · Jun 25, 2024 · US
Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith
US-2023134821-A1 · May 4, 2023 · US
Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith
US-2022112157-A1 · Apr 14, 2022 · US
Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
US-10927075-B2 · Feb 23, 2021 · US
Compound having enhancing activity for glucagon-like peptide-1 receptor actions
US-2020129458-A1 · Apr 30, 2020 · US
Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
US-10351522-B2 · Jul 16, 2019 · US
Fluorine atom-containing compound and use thereof
US-10336686-B2 · Jul 2, 2019 · US
Methods and compositions for treatment of cancer and autoimmune disease
US-10207988-B2 · Feb 19, 2019 · US
Fluorine atom-containing compound and use thereof
US-2019031600-A1 · Jan 31, 2019 · US
Compound having enhancing activity for glucagon-like peptide-1 receptor actions
US-2019022039-A1 · Jan 24, 2019 · US
Tripodal nitrate receptor
US-10060892-B2 · Aug 28, 2018 · US
Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
US-2018179151-A1 · Jun 28, 2018 · US
Sweetness receptor antagonist
US-9907766-B2 · Mar 6, 2018 · US
Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
US-2017362172-A1 · Dec 21, 2017 · US
Bifunctional organic catalysts
US-9687832-B2 · Jun 27, 2017 · US
Tripodal Nitrate Receptor
US-2017115262-A1 · Apr 27, 2017 · US
Sweetness receptor antagonist
US-2017101372-A1 · Apr 13, 2017 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07C335/20?
- CPC C07C335/20 is the Cooperative Patent Classification code for “being further substituted by nitrogen atoms, not being part of nitro or nitroso groups.”
- How many patents are filed under CPC C07C335/20 (being further substituted by nitrogen atoms, not being part of nitro or nitroso groups)?
- Our database includes 25 publications tagged with this CPC code.
- Is patent activity under CPC C07C335/20 growing?
- Publication counts under this code: 2 in 2024 vs 1 in 2025 (latest complete years).